21:08 , Aug 8, 2018 |  BC Extra  |  Politics & Policy

Rep. Collins indicted with insider trading in biotech shares

A grand jury charged Rep. Christopher Collins (R-N.Y.) Wednesday with insider trading in shares of Australian biotech Innate Immunotherapeutics Ltd. (ASX:IIL) by alerting family members of a clinical trial failure before the results were made...
20:06 , Jul 7, 2017 |  BC Week In Review  |  Clinical News

Innate's MIS416 fails in Phase IIb for MS

Innate Immunotherapeutics Ltd. (ASX:IIL) reported top-line data from a double-blind, Australian and New Zealand Phase IIb trial in 93 patients with secondary progressive multiple sclerosis (MS) showing that once-weekly 500 μg IV MIS416 for 52...
01:48 , Feb 1, 2017 |  BC Extra  |  Politics & Policy

Dems delaying Price confirmation

Democrats on the U.S. Senate Finance Committee boycotted a confirmation hearing for Rep. Tom Price (R-Ga.) on Tuesday, delaying a vote to advance Price's nomination as HHS secretary. The delay will not prevent an eventual...
01:12 , Jan 25, 2017 |  BC Extra  |  Politics & Policy

Price unenthusiastic about Medicare drug negotiations

At a confirmation hearing Tuesday, HHS secretary nominee Rep. Tom Price (R-Ga.) dodged questions about President Trump’s proposals to give the federal government authority to negotiate Medicare drug prices, and contradicted the president’s statements expressing...
00:29 , Jan 19, 2017 |  BC Extra  |  Politics & Policy

Price bobs and weaves on drug prices

President-elect Donald Trump’s nominee for HHS secretary, Rep. Tom Price (R-Ga.), dodged questions Wednesday about negotiation of drug price controls. Trump recently called for HHS to negotiate Medicare drug prices, a policy that Price has...
07:00 , Oct 20, 2014 |  BioCentury  |  Product Development

Walking the toll road

Even after a series of clinical setbacks in the mid-2000s cooled investor and pharma interest in the once white-hot field of toll-like receptors, several companies continued toiling away. Now the spark may be rekindling as...
08:00 , Jan 6, 2014 |  BioCentury  |  Finance

2014 Financial Markets Preview: Hoping the pause is brief

Bankers and buysiders are not expecting a repeat performance of biotech's stellar 2013. But the two dozen who spoke with BioCentury say the capital markets are primed to open back up this month, albeit on...
08:00 , Dec 23, 2013 |  BC Week In Review  |  Financial News

Innate Immunotherapeutics completes IPO

Innate Immunotherapeutics Ltd. (ASX:IIL), Auckland, New Zealand   Business: Autoimmune, Cancer, Infectious   Date completed: 12/17/13   Type: IPO   Raised: A$10 million ($9 million)   Shares: 50 million   Price: A$0.20   Shares after...
02:02 , Dec 19, 2013 |  BC Extra  |  Financial News

Innate raises $9 million in Australian IPO

Innate Immunotherapeutics Ltd. (Auckland, New Zealand) raised A$10 million ($9 million) through the sale of 50 million shares at A$0.20 in an IPO on the Australian Stock Exchange. The price values Innate at A$34.5 million...
08:00 , Dec 9, 2013 |  BC Week In Review  |  Financial News

Innate Immunotherapeutics proposes IPO

Innate Immunotherapeutics Ltd. , Auckland, New Zealand   Business: Autoimmune, Cancer, Infectious   Date announced: 11/26/13   Type: IPO   To be raised: Up to A$12 million ($11 million)   Shares: 60 million   Price:...